Abstracts Archive - Page 437 of 2607 - ACR Meeting Abstracts

Abstract Number: 2118 • ACR Convergence 2023
New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry
Robert Spandorfer¹, Kevin Kane², George Reed², Dimitrios Pappas², Joel Kremer², Jeffrey Curtis³ and Iris Navarro-Millán⁴, ¹Hospital for Special Surgery, Brooklyn, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
Abstract Number: 2120 • ACR Convergence 2023
Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections
Misaki Yoshida¹, takeshi Zoshima², Ichiro Mizushima² and Mitsuhiro Kawano², ¹Kanazawa University, Fukui, Japan, ²Kanazawa University, Kanazawa, Japan
Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…
Abstract Number: 1739 • ACR Convergence 2023
Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies
Khetam Ghannam¹, Marieluise Kirchner², Holger Bang³, Thomas Häupl⁴, Sarah Ohrndorf¹, Jan Zernicke¹, Ulrike Kuckelkorn⁵, Philipp Mertins⁶, Eugen Feist⁷ and Gerd Burmester⁸, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ³Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁵Institute of Biochemistry, Berlin, Germany, ⁶Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ⁷Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁸Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
Abstract Number: 1737 • ACR Convergence 2023
ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA
Veerle Derksen¹, Klara Martinsson², René Toes¹, Daniel Sjöberg³, Thomas Huizinga¹, Alf Kastbom⁴, Anna Svärd³ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Linköping University, Linköping, Sweden, ³Centre for Clinical Research Dalarna, Uppsala, Sweden, ⁴Linköping University, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients harbor antibodies against several post-translational modifications (AMPA), for example anti-citrullinated protein antibodies (ACPA), anti-carbamylated antibodies (anti-CarP) and anti-acetylated protein antibodies…
Abstract Number: 2121 • ACR Convergence 2023
Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis
Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan
Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Sayuli Bhide¹, Punyasha Roul², Namrata Singh³, Grant Cannon⁴, Gary Kunkel⁵, Ted R Mikuls⁶, Bryant England², Dolores Shoback⁷, Patti Katz⁸, Jose Garcia⁹, Ariela Orkaby¹⁰, Joshua Baker¹¹ and K Wysham¹², ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷San Francisco VA Medical Center, San Francisco, CA, ⁸University of California San Francisco, San Rafael, CA, ⁹VA Puget Sound Healthcare System, Seattle, WA, ¹⁰Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…
Abstract Number: 1744 • ACR Convergence 2023
Histological and Molecular Comparison in the Synovial Tissue of Patients with Active Rheumatoid Arthritis to Remission
Selina Ohl¹, Klaus Frommer¹, Markus Rickert², Stefan Rehart³, Ulf Müller-Ladner¹ and Elena Neumann¹, ¹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, ³Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which leads to local and systemic manifestations. Subsequently, the inflamed synovium drives the destruction of…
Abstract Number: 2124 • ACR Convergence 2023
Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals
Adam Savage¹, Ziyuan He¹, Marla Glass¹, Julian Reading¹, LauraKay Moss², Marie Feser², Vlad Tsaltskan³, Katherine Nguyen Nguyen³, Kristen Demoruelle², kristine Kuhn⁴, David Boyle³, Cate Speake⁵, Xiao-Jun Li¹, Peter Skene¹, Troy Torgerson¹, Tom Bumol¹, V. Michael Holers⁶, Jane Buckner⁷, Gary Firestein⁸, kevin Deane² and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California San Diego, La Jolla, CA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Benaroya Research Institute, Seattle, WA, ⁶University of Colorado, Denver, CO, ⁷Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁸University of California San Diego, San Diego, CA
Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
Abstract Number: 1714 • ACR Convergence 2023
Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling
Gaochan Wang¹, Qingfu Xu², Stacey Duemmel¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary hypertension (PH) is a severe, progressive disorder characterized by elevated pulmonary artery pressures, right ventricular hypertrophy, and increased mortality. We previously demonstrated that…
Abstract Number: 1698 • ACR Convergence 2023
High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis
Huihua Ding, Yiwei Shen, Min Dai and Nan Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…
Abstract Number: 1707 • ACR Convergence 2023
PD1-Expressing Regulatory T Cells Found in Inflamed Joints Suppress Tph Cell-B Cell Interactions
Ki Pui Lam¹, Amélie M Julé¹, Claudia Harris², Maria Taylor¹, Maryrose Hahn², Laurie A Ohlms³, Pui Lee², Margaret Chang⁴, Talal Chatila⁵, Peter Nigrovic⁴ and Lauren Henderson⁴, ¹Division of Immunology, Boston Children’s Hospital, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Boston, MA, ³Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital, Boston, MA, ⁴Boston Children's Hospital, Boston, MA, ⁵Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T peripheral helper (Tph) cells promote B cell maturation and the generation of antibodies in the inflamed joints of adults with seropositive rheumatoid arthritis…
Abstract Number: 1507 • ACR Convergence 2023
Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
Chun Wu¹, Cristina Arriens², J. Michelle Kahlenberg³, Yanhua Hu¹, Coburn Hobar¹, Adrian Coles⁴ and Ian M. Catlett⁵, ¹Bristol Myers Squibb, Princeton, NJ, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³University of Michigan, Ann Arbor, MI, ⁴Bristol Myers Squibb, Lawrenceville, NJ, ⁵Bristol Myers Squibb, Pennington, NJ
Background/Purpose: Deucravacitinib (DEUC) is a first-in-class, oral, selective, allosteric inhibitor of TYK2. TYK2 is required for signal transduction downstream of cytokines implicated in SLE pathophysiology,…
Abstract Number: 1519 • ACR Convergence 2023
Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis
Malcolm MacKenzie¹, Harry Atkins² and Nancy Maltez¹, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Rapidly progressive diffuse systemic sclerosis (SSc) is a devastating autoimmune disease with high morbidity and mortality. Autologous hematopoietic stem cell transplantation (AHSCT) is recognized…
Abstract Number: 1097 • ACR Convergence 2023
Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program
Kelsey Pasch¹, Stephen Lindsey² and Takeda Ferguson³, ¹Louisiana State University -- New Orleans, Baton Rouge, LA, ²LSU Health Science Center, New Orleans, LA, ³LSU Health Science Center School of Public Health, New Orleans, LA
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at increased risk of infection. The Centers for Disease Control and Prevention (CDC) and the ACR strongly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].